These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 23640298)

  • 1. International survey of cytomegalovirus management in solid organ transplantation after the publication of consensus guidelines.
    Le Page AK; Jager MM; Kotton CN; Simoons-Smit A; Rawlinson WD
    Transplantation; 2013 Jun; 95(12):1455-60. PubMed ID: 23640298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An international survey of cytomegalovirus management practices in lung transplantation.
    Zuk DM; Humar A; Weinkauf JG; Lien DC; Nador RG; Kumar D
    Transplantation; 2010 Sep; 90(6):672-6. PubMed ID: 20581765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Summary of the British Transplantation Society Guidelines for the Prevention and Management of CMV Disease After Solid Organ Transplantation.
    Andrews PA; Emery VC; Newstead C
    Transplantation; 2011 Dec; 92(11):1181-7. PubMed ID: 22002346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytomegalovirus infection management in solid organ transplant recipients across European centers in the time of molecular diagnostics: An ESGICH survey.
    Navarro D; San-Juan R; Manuel O; Giménez E; Fernández-Ruiz M; Hirsch HH; Grossi PA; Aguado JM;
    Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28859257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An international survey of cytomegalovirus prevention and treatment practices in intestinal transplantation.
    Florescu DF; Abu-Elmagd K; Mercer DF; Qiu F; Kalil AC
    Transplantation; 2014 Jan; 97(1):78-82. PubMed ID: 24092376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of cytomegalovirus disease in solid organ transplant patients: prophylactic versus preemptive therapy.
    Baillie GM
    Am J Health Syst Pharm; 2006 Oct; 63(19 Suppl 5):S10-6. PubMed ID: 16990639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunocompromised hosts: perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients.
    Torres-Madriz G; Boucher HW
    Clin Infect Dis; 2008 Sep; 47(5):702-11. PubMed ID: 18652557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients.
    Singh N
    Clin Infect Dis; 2001 Mar; 32(5):742-51. PubMed ID: 11229841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytomegalovirus in solid organ transplant recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice.
    Razonable RR; Humar A
    Clin Transplant; 2019 Sep; 33(9):e13512. PubMed ID: 30817026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention and management of cytomegalovirus infection in solid-organ transplantation.
    Mwintshi K; Brennan DC
    Expert Rev Anti Infect Ther; 2007 Apr; 5(2):295-304. PubMed ID: 17402844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?
    Jain A; Orloff M; Kashyap R; Lansing K; Betts R; Mohanka R; Menegus M; Ryan C; Bozorgzadeh A
    Transplant Proc; 2005 Sep; 37(7):3182-6. PubMed ID: 16213344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytomegalovirus risk, prevention, and management in pediatric solid organ transplantation.
    Martin JM; Danziger-Isakov LA
    Pediatr Transplant; 2011 May; 15(3):229-36. PubMed ID: 21199215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation.
    Kotton CN; Kumar D; Caliendo AM; Asberg A; Chou S; Snydman DR; Allen U; Humar A;
    Transplantation; 2010 Apr; 89(7):779-95. PubMed ID: 20224515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytomegalovirus prophylaxis and treatment after hematopoietic stem cell transplantation in Canada: a description of current practices and comparison with Centers for Disease Control/Infectious Diseases Society of America/American Society for Blood and Marrow Transplantation guideline recommendations.
    Fraser GA; Walker II;
    Biol Blood Marrow Transplant; 2004 May; 10(5):287-97. PubMed ID: 15111928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of high-dose ganciclovir for the treatment of cytomegalovirus replication in solid organ transplant patients with ganciclovir resistance-inducing mutations.
    Gracia-Ahufinger I; Gutiérrez-Aroca J; Cordero E; Vidal E; Cantisán S; del Castillo D; Martín-Gandul C; Rivero A; Torre-Cisneros J
    Transplantation; 2013 Apr; 95(8):1015-20. PubMed ID: 23407543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of valganciclovir prophylaxis on the development of severe late-cytomegalovirus disease in high-risk solid organ transplant recipients.
    Cervera C; Pineda M; Linares L; Marcos MA; Esteva C; Antón A; Cofán F; Ricart MJ; Navasa M; Pérez-Villa F; Pumarola T; Moreno A
    Transplant Proc; 2007 Sep; 39(7):2228-30. PubMed ID: 17889146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation.
    Kotton CN; Kumar D; Caliendo AM; Asberg A; Chou S; Danziger-Isakov L; Humar A;
    Transplantation; 2013 Aug; 96(4):333-60. PubMed ID: 23896556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients.
    Len O; Gavaldà J; Aguado JM; Borrell N; Cervera C; Cisneros JM; Cuervas-Mons V; Gurguí M; Martin-Dávila P; Montejo M; Muñoz P; Bou G; Carratalà J; Torre-Cisneros J; Pahissa A;
    Clin Infect Dis; 2008 Jan; 46(1):20-7. PubMed ID: 18171208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
    Witzke O; Hauser IA; Bartels M; Wolf G; Wolters H; Nitschke M;
    Transplantation; 2012 Jan; 93(1):61-8. PubMed ID: 22094954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients.
    Boivin G; Goyette N; Gilbert C; Humar A; Covington E
    Transpl Infect Dis; 2005; 7(3-4):166-70. PubMed ID: 16390409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.